Colorectal cancer is the third most common cancer worldwide and a leading cause of death. In the past decade, innovation in surgical treatment for colorectal cancer, including robotic platforms, and advances in targeted therapy, immunotherapy, cell-directed therapy, and combination therapy have significantly improved survival rates in patients with colorectal cancer. This book presents updated information on the diagnosis, screening, and treatment and management of colorectal cancer for treating physicians and patients alike.

Inflammation and cancer are two major disorders that cause huge concerns in our society. However, what one may not know is that both diseases are closely associated and, in particular, both occur in the gastrointestinal tract and liver. This book describes the mechanics of how inflammation can progress to cancer in these organs. The authors in this book comprehensively discuss the different biomarkers for early diagnosis, and current therapeutic treatments for these diseases. All of these would allow us to better understand the pathogenesis of both diseases. As such, this book provides comprehensive information concerning the interrelationship between inflammation and cancer in a cohesive manner, and the information derived would benefit not only basic scientists but also clinicians who are working in these fields.

An understanding of the molecular pathogenesis of colorectal cancer by researchers and clinicians is essential to facilitate progress in improving patient outcomes in this common cancer that still carries a poor prognosis if not identified early. This book covers the major areas of importance in the field, incorporating new knowledge that has arisen due to the advancement of molecular techniques and the ability to correlate molecular changes with clinical behaviour of tumours. Each chapter is a summary written by experts, concisely summarising current data as well as highlighting potential areas for advancement. Appreciating the differences between tumours on a molecular level is the key to developing and delivering precision medicine, and nowhere is this more critically required than in the field of colorectal cancer.

This fourth volume in a series devoted to cancer treatment discusses various methodologies for the diagnosis, therapy and prognosis of colorectal cancer. It covers the latest information including standard and emerging therapies and technological advances.

Tumor Board Reviews provides comprehensive coverage of all topics in oncology. Each of the 32 chapters focuses on a specific major disease. A brief overview of epidemiology and risk factors is followed by a sequence of specific presentations organized by tumors stage or disease classification. Each discussion features a case presentation that mimics the format of a tumor board presentation and thus illustrates key diagnostic and management decisions. There is also a discussion of the evidence that supports the clinical management decisions taken in the case, based on current expert panel guidelines. Algorithms and decision tree graphics are used extensively to provide visual support of the decision process. The combination of case presentations and evidence-based management discussions make this volume a unique tool for keeping current with clinical guidelines and provides the reader with a clear understanding of applications of new information for use in daily practice.

Gastrointestinal Oncology is an evidence-based, practical reference intended to assist in the diagnosis and management of patients with gastrointestinal malignancies. It is designed to be as user friendly as possible and is distinguished by the extremely practical, concrete nature of the information presented and by the multidisciplinary approach adopted. In addition to disease-oriented chapters spanning sites from the esophagus to the anus, non-anatomic subjects such as modern imaging techniques are also addressed. Translational science is supplied where useful in the decision-making process. All of the authors are internationally recognized experts. This book is an ideal resource for oncologists, surgeons, gastroenterologists, and primary-care providers looking for the latest and best information on how to deal with a wide variety of gastrointestinal neoplasms.

This textbook provides current information on best practice in multidisciplinary cancer care. Divided into six sections, the contributors look at the aetiology of cancer, patient care, population health and thethe management of specific types of disease. Written and edited by internationally recognised leaders in the field, the new edition of the Oxford Textbook of Oncology has been fully revised and updated, taking into consideration the advancements in each of the major therapeutic areas, and representing the multidisciplinary management of cancer. Structured in six sections, the book provides an accessible scientific basis to the key topics of oncology, examining how cancer cells grow and function, as well as discussing the aetiology of cancer, and the general principles governing modern approaches to oncology treatment. The book examines the challenges presented by the treatment of cancer on a larger scale within population groups, and the importance of recognising and supporting the needs of individual patients, both during and after treatment. A series of disease-oriented, case-based chapters, ranging from acute leukaemia to colon cancer, highlight the various approaches available for managing the cancer patient, including the translational application of cancer science in order to personalise treatment. The advice imparted in these cases has relevance worldwide, and reflects a modern approach to cancer care. The Oxford Textbook of Oncology provides a comprehensive account of the multiple aspects of best practice in the discipline, making it an indispensable resource for oncologists of all grades and subspecialty interests. Review: Each chapter is nicely illustrated with schemes, cartoons and images. The text, although written by top oncologists, is readily understandable for a non-expert. Thus, the textbook will no doubt be appreciated by a broader audience. * Recent Patents on Anti-Cancer Drug Discovery Vol. 11 Issue No. 4, Alexander Shtil * I recommend this book highly to all oncology and oncologists in training as a thorough, informative, and readable reference. Every large intuitional library and every oncology library should have it. * NEJM, 2002 * This comprehensive textbook of oncology is the first new major textbook on cancer to appear in a decade and is designed for a broad audience of clinicians, oncologists in training, and academics. The coverage is comprehensive...The overall appearance of the book is outstanding. It is a welcome combination of epidemiology, aspects of basic science, pharmacology and radiation therapy that trainees will fine a nice change...should enjoy a wide readership...because of its appealing design and comprehensive approach to oncology. It is the most user-friendly comprehensive text currently available. The pathology, basic science, epidemiology, and radiation therapy sections are all presented with extreme clarity. * Doody's Journal , 2002 * A landmark reference...It sets new standards for publishing in oncology offering a ground-breaking innovative approach to the filed combined with the quality, accuracy , and intellectual rigour you have come to expect from the world's most prestigious reference publisher. * Biomedicine and Pharmacotherapy, 2002 * Under new editorship, the second edition is far more than an updated version of the first...the prose in the Oxford Textbook is exemplary...this textbook is unique among its peers in giving the sense that the authors are addressing the reader personally...an exception level of quality...Respect for the evidence-based medicine is apparent throughout the text...illustrative and anatomical drawing...of remarkable high quality...excellent discussion of doctor-patient communication in relation OT genetic counselling, psychological issues, and terminal cancers. * JAMA, Volume 287, Issue 24, 2002 * The Oxford Textbook of Oncology covers virtually the entire spectrum of malignant diseases in adults and children. It meets very high editorial and production standards: the organization, illustrations, and eye-pleasing typography are outstanding... I have high praise for this textbook. * NEJM, Volume 347, Number 2, 2002 * Review from previous edition The Oxford Textbook of Oncology is a classic and fresh approach to the field. It is a must for all libraries and all those who like to have a single up-to-date reference book that contains sufficient detail for the clinician in all subspecialties: surgery and chapters are sufficiently details to provide a reference for trainees in the field. * Oncology, Volume 63, 2002 * The Oxford Textbook of Oncology is what it is meant to be: a textbook with comprehensive information of the actual status of oncology... an indispensable and attractive source of information. * Professor Jaak Ph. Janssens, European Journal of Cancer Prevention * This volume provides a comprehensive account of the multiple aspects of best practice in the discipline, making it an indispensable resource for oncologists of all grades and subspecialty interests. * Anticancer Research Vol. 36 (2016) * An outstanding gift to the international scientific community... The new textbook is an excellent demonstration of this multifaceted and astonishingly variable problem, as well as of the latest achievements in its understanding and practical management. * Alexander A. Shtil, Recent Patents on Anticancer Drug Discovery * I would recommend anyone considering buying an oncology textbook, and particularly those who work in oncology support services, to consider this textbook as it is well set out, easy to read, easy to comprehend, and covers all of the important aspects of modern day oncology. * Dr Andrew Davies, Consultant in Palliative Medicine, Royal Surrey County Hospital; Review for Supportive Care in Cancer *

March is Colorectal Cancer Awareness Month and at Frontiers in Oncology we want to highlight the recent discoveries in the field and raise awareness of the importance of early diagnosis, multidisciplinary management, and technological innovation support. Colorectal cancer (CRC) is the third most common cancer worldwide and represents one of the most relevant challenges for present and future global health, with 50 % of patients affected by CRC developing metastasis. Despite the introduction of novel therapeutic approaches and anticancer drugs, colorectal metastatic cancer (mCRC) continue to have a poor prognosis. In the last years, the extensive investigation on biomarkers that could identify patients at high risk for metastasis and predict the response to therapies has deeply impacted the therapeutic approaches to patients with mCRC. The most established biomarkers for mCRC are microsatellite instability (MSI) or mismatch repair deficiency (dMMR), HER2 amplification, RAS/BRAF mutations, and sidedness. Immune checkpoint inhibitors (ICIs) have been extensively used to treat patients with microsatellite unstable or mismatch repair-deficient (dMMR) CRC, while patients harboring a BRAFV600E mutation benefit from combination therapy with chemotherapy and immunotherapy drugs. The success of biomarker-driven patient selection to improve the therapeutic response and the overall survival of patients with mCRC highlights the imperative need for further research to identify novel biomarkers for better patient-tailored therapy.